Tranquility Partners LLC Grows Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Tranquility Partners LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 34.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,009 shares of the medical research company’s stock after purchasing an additional 515 shares during the period. Tranquility Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,066,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Bornite Capital Management LP lifted its position in shares of Thermo Fisher Scientific by 50.0% in the first quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock valued at $17,719,000 after acquiring an additional 10,000 shares in the last quarter. Fairfield Bush & CO. lifted its position in shares of Thermo Fisher Scientific by 1.2% in the first quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock valued at $1,729,000 after acquiring an additional 36 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Thermo Fisher Scientific by 563.5% in the first quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock valued at $11,721,000 after acquiring an additional 16,853 shares in the last quarter. Covestor Ltd lifted its position in shares of Thermo Fisher Scientific by 60.5% in the first quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock valued at $190,000 after acquiring an additional 121 shares in the last quarter. Finally, Merit Financial Group LLC increased its holdings in shares of Thermo Fisher Scientific by 3.6% in the first quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock worth $395,000 after purchasing an additional 23 shares during the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

TMO has been the topic of several research reports. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Barclays cut Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Royal Bank of Canada lifted their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. HSBC boosted their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, The Goldman Sachs Group boosted their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Trading Down 1.3 %

Shares of TMO traded down $7.30 during mid-day trading on Wednesday, reaching $547.25. 1,609,039 shares of the company’s stock traded hands, compared to its average volume of 1,540,204. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The stock has a market cap of $208.89 billion, a P/E ratio of 35.44, a P/E/G ratio of 2.34 and a beta of 0.80. The stock’s 50-day moving average is $571.67 and its two-hundred day moving average is $526.87. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Thermo Fisher Scientific’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.40 earnings per share. Research analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.29%. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,277 shares of company stock worth $28,513,384. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.